8-K: Capricor Therapeutics' HOPE-3 Trial Hits Key Endpoints

Capricor Therapeutics announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial for Deramiocel in Duchenne muscular dystrophy, meeting both primary and key secondary endpoints.

Summary

• Capricor Therapeutics announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial evaluating Deramiocel for Duchenne muscular dystrophy (DMD).
• The randomized, double-blind, placebo-controlled study involved 106 participants, with an average age of approximately 15 years, across 20 U.S. clinical sites.
• Participants received intravenous Deramiocel (150 million cells per infusion) or placebo every three months for a 12-month period, all while on a stable corticosteroid regimen.
• The primary endpoint, Performance of Upper Limb (PUL v2.0) Total Score, showed a 54% slowing of progression (Deramiocel vs. Placebo) with a p-value of 0.029 (n=105).
• The key secondary cardiac endpoint, Left Ventricular Ejection Fraction (LVEF %), demonstrated a 91% slowing of progression with a p-value of 0.041 (n=83).
• Deramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experience.
• The company plans to submit its response to the Complete Response Letter (CRL) incorporating HOPE-3 data, following prior alignment with the FDA.

Sentiment

Score: 9

Explanation: The filing reports highly positive, statistically significant topline results from a pivotal Phase 3 clinical trial for a severe rare disease, meeting both primary and key secondary endpoints. This represents a major advancement towards regulatory approval and addresses a significant unmet medical need, indicating strong potential for the company's lead product candidate.

Positives

• The pivotal Phase 3 HOPE-3 trial met its primary endpoint (PUL v2.0 Total Score) with statistical significance (p=0.029), demonstrating a 54% slowing of skeletal muscle disease progression.
• The key secondary cardiac endpoint (Left Ventricular Ejection Fraction) also achieved statistical significance (p=0.041), showing a 91% slowing of progression.
• Statistical significance was achieved in all type 1 error controlled secondary endpoints.
• Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy designed to treat Duchenne cardiomyopathy, the leading cause of mortality in Duchenne.
• Deramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experience.
• The results reinforce the durable benefits seen in HOPE-2 and its open-label extension, which has continued for over 48 months.
• The company believes these pivotal study results, in addition to evidence from prior studies, position them to address the clinical issues in the Complete Response Letter and support regulatory approval.

Risks

• Actual results or events could differ materially from forward-looking statements due to important factors.
• Required regulatory inspections may be delayed or not be successful, which would delay or prevent product approval.
• The ability to achieve product milestones and receive milestone payments from commercial partners is subject to risks.
• More information about these and other risks is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Future Outlook

The company expects to submit detailed HOPE-3 results for presentation at a future scientific meeting and for publication in a peer-reviewed journal. Concurrently, Capricor and its commercial partner, Nippon Shinyaku (U.S. subsidiary, NS Pharma, Inc.), are advancing launch readiness activities to support timely patient access to Deramiocel, pending potential regulatory approval. The company plans to submit its response to the Complete Response Letter incorporating HOPE-3 data, consistent with prior FDA guidance.

Management Comments

• "HOPE-3 delivered strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy, demonstrating statistically significant improvements in both skeletal and cardiac function." Linda Marbn, Ph.D., Chief Executive Officer of Capricor.
• "These results reinforce the durable benefits seen in HOPE-2 and its open-label extension, which has continued for over 48 months, and highlight the strength, consistency and reproducibility of Deramiocels clinical profile after more than a decade of rigorous clinical development." Linda Marbn, Ph.D., Chief Executive Officer of Capricor.
• "We believe these pivotal study results, in addition to the evidence from the HOPE-2 and HOPE-2 OLE studies, position us to address the clinical issues in the Complete Response Letter received earlier this year, consistent with prior FDA guidance that HOPE-3 results should be sufficient to support regulatory approval." Linda Marbn, Ph.D., Chief Executive Officer of Capricor.
• "A nearly 54 percent slowing of skeletal muscle disease progression is extraordinary in Duchenne and directly linked to maintaining independence and quality of life in the most severely affected patients with greatest unmet need." Craig McDonald, M.D., Distinguished Professor of Physical Medicine & Rehabilitation and Pediatrics at UC Davis Health, and National PI of the HOPE-3 trial.
• "The preservation of function reflected in PUL v2.0 translates into real, practical benefits for boys and young men living with this disease, and the effect of Deramiocel on cardiomyopathy will potentially translate to improved long-term survival." Craig McDonald, M.D.
• "The HOPE-3 study is the first-ever Phase 3 trial in a largely non-ambulatory population with DMD to successfully meet its primary endpoint." Craig McDonald, M.D.
• "Cardiomyopathy is the leading cause of mortality in Duchenne, and stabilizing cardiac function has remained a major unmet need." Jonathan Soslow, M.D., MSCI, Professor of Pediatrics (Cardiology) at Vanderbilt University Medical Center.
• "The statistically and clinically significant preservation of left ventricular ejection fraction in patients treated with Deramiocel observed in HOPE-3 underscores the potential of Deramiocel to address one of the most critical aspects of the disease." Jonathan Soslow, M.D., MSCI.
• "For families living with Duchenne who are looking for therapies that preserve functional ability, protect the heart and maintain independence, todays results provide real momentum and meaningful progress, offering renewed confidence as we work to advance Deramiocel toward potential regulatory approval." Linda Marbn, Ph.D., Chief Executive Officer of Capricor.

Industry Context

Duchenne Muscular Dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting skeletal, respiratory, and cardiac muscles. It impacts approximately 15,000 individuals in the United States, primarily boys. Cardiomyopathy, leading to heart failure, is the leading cause of death in DMD, representing a significant unmet medical need. Deramiocel, an allogeneic cardiosphere-derived cell therapy, aims to address both skeletal and cardiac muscle function, potentially offering a first-in-class therapy for Duchenne cardiomyopathy.

Comparison to Industry Standards

• The HOPE-3 study is the first-ever Phase 3 trial in a largely non-ambulatory population with DMD to successfully meet its primary endpoint.
• A nearly 54% slowing of skeletal muscle disease progression is described as "extraordinary in Duchenne" and directly linked to maintaining independence and quality of life.
• The statistically and clinically significant preservation of left ventricular ejection fraction addresses a major unmet need in Duchenne cardiomyopathy, which is the leading cause of mortality.

Stakeholder Impact

• Shareholders: Highly positive news, likely to increase share value due to significant progress towards regulatory approval and commercialization of a key product.
• Patients (boys and young men with DMD): Offers "real momentum and meaningful progress" and "renewed confidence" for a potential therapy that preserves functional ability, protects the heart, and maintains independence, addressing a major unmet need.
• Commercial Partner (Nippon Shinyaku/NS Pharma, Inc.): Positive results advance their commercialization efforts and potential market entry for Deramiocel.
• Employees: Positive news for the company's future and product development efforts.

Next Steps

• Submit detailed HOPE-3 results for presentation at a future scientific meeting.
• Submit detailed HOPE-3 results for publication in a peer-reviewed journal.
• Submit the company's response to the Complete Response Letter (CRL) incorporating HOPE-3 data.
• Advance launch readiness activities with commercial partner Nippon Shinyaku (NS Pharma, Inc.) to support timely patient access, pending regulatory approval.

Key Dates

Recommendation

The announcement of positive topline results from a pivotal Phase 3 clinical trial for Deramiocel in Duchenne muscular dystrophy, meeting both primary and key secondary endpoints with statistical significance, is a transformative event for Capricor Therapeutics. This significantly de-risks the regulatory pathway, as the results are intended to address a prior Complete Response Letter from the FDA. The data demonstrates clinically meaningful benefits in both skeletal and cardiac function, addressing the leading cause of mortality in DMD. Given the high unmet medical need for DMD and the potential for Deramiocel to be a first-in-class therapy, successful regulatory approval and subsequent commercialization would likely lead to substantial revenue growth and significant upside for the stock. The favorable safety profile further strengthens the investment case.

Keywords

Duchenne muscular dystrophy, DMD, Deramiocel, CAP-1002, Phase 3, HOPE-3, clinical trial, cell therapy, cardiomyopathy, skeletal muscle, LVEF, PUL v2.0, Capricor Therapeutics, rare disease, biotechnology, FDA approval, regenerative medicine